{"id":"darolutamide-bay-1841788","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4297185","moleculeType":"Small molecule","molecularWeight":"398.85"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Darolutamide binds to the androgen receptor with high affinity and specificity, preventing androgen-driven transcription and proliferation of prostate cancer cells. Unlike some older androgen receptor antagonists, it has improved blood-brain barrier penetration and a longer half-life, allowing for more effective suppression of castration-resistant prostate cancer progression.","oneSentence":"Darolutamide is a non-steroidal androgen receptor inhibitor that blocks androgen signaling in prostate cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:39.700Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)"},{"name":"Metastatic hormone-sensitive prostate cancer (mHSPC)"}]},"trialDetails":[{"nctId":"NCT06592924","phase":"PHASE3","title":"Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2025-05-28","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":830},{"nctId":"NCT04484818","phase":"PHASE3","title":"Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-03-01","conditions":"Prostate Carcinoma","enrollment":27},{"nctId":"NCT06661122","phase":"","title":"A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-11-18","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Low-volume Metastasis","enrollment":100},{"nctId":"NCT04122976","phase":"","title":"A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2020-01-30","conditions":"Prostate Cancer","enrollment":805},{"nctId":"NCT06169124","phase":"PHASE2","title":"Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-08","conditions":"Adult Ovarian Granulosa Cell Tumor","enrollment":37},{"nctId":"NCT06282588","phase":"PHASE2, PHASE3","title":"Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers","status":"RECRUITING","sponsor":"Cancer Research Antwerp","startDate":"2023-12-13","conditions":"Prostate Cancer","enrollment":493},{"nctId":"NCT05348876","phase":"PHASE4","title":"A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)","status":"RECRUITING","sponsor":"Bayer","startDate":"2022-08-03","conditions":"Non-metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT05794906","phase":"PHASE3","title":"A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2023-04-03","conditions":"Biochemically Recurrent Prostate Cancer","enrollment":985},{"nctId":"NCT06173362","phase":"PHASE2","title":"Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer","status":"RECRUITING","sponsor":"University of California, Davis","startDate":"2023-11-09","conditions":"Advanced Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8","enrollment":75},{"nctId":"NCT06334120","phase":"","title":"An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea","status":"RECRUITING","sponsor":"Bayer","startDate":"2024-09-25","conditions":"Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer","enrollment":600},{"nctId":"NCT05526248","phase":"PHASE2","title":"A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-12-19","conditions":"Biochemically Recurrent Prostate Cancer","enrollment":28},{"nctId":"NCT06463457","phase":"PHASE2","title":"Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Atish Choudhury, MD","startDate":"2024-12-13","conditions":"Prostate Cancer, Advanced Prostate Cancer, Hormone Sensitive Prostate Cancer","enrollment":33},{"nctId":"NCT04736199","phase":"PHASE3","title":"Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-23","conditions":"Prostatic Neoplasms","enrollment":669},{"nctId":"NCT05059236","phase":"PHASE2","title":"A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2021-11-04","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":223},{"nctId":"NCT06631521","phase":"PHASE1","title":"Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer","status":"RECRUITING","sponsor":"AdventHealth","startDate":"2024-10-22","conditions":"Prostate CA, Prostate Cancer (Adenocarcinoma), Prostate Cancer Surgery","enrollment":30},{"nctId":"NCT07344779","phase":"","title":"A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-02-17","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1600},{"nctId":"NCT05050084","phase":"PHASE3","title":"Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2021-12-06","conditions":"Prostate Adenocarcinoma","enrollment":2050},{"nctId":"NCT06378866","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-06-03","conditions":"Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":532},{"nctId":"NCT07282197","phase":"PHASE2","title":"Darolutamide+ADT Post-RP w/o ePLND in hrPC: Briganti 2019","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2026-01","conditions":"Prostate Cancer","enrollment":40},{"nctId":"NCT02799602","phase":"PHASE3","title":"Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-11-30","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":1306},{"nctId":"NCT05669664","phase":"PHASE2","title":"Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-07-20","conditions":"Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma","enrollment":21},{"nctId":"NCT04464226","phase":"PHASE3","title":"Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer","status":"RECRUITING","sponsor":"Bayer","startDate":"2020-10-20","conditions":"Cancer","enrollment":402},{"nctId":"NCT07016399","phase":"PHASE2","title":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","status":"RECRUITING","sponsor":"Vandana Abramson","startDate":"2025-09-09","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma","enrollment":51},{"nctId":"NCT05202301","phase":"","title":"A Study Using Available Data to Learn to What Extent Patients With Prostate Cancer Who Received Second Generation Androgen Receptor Inhibitors Took Their Medication as Prescribed or Stopped Taking Their Medication Completely","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-01-15","conditions":"Prostate Cancer","enrollment":13779},{"nctId":"NCT06013475","phase":"","title":"An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings","status":"COMPLETED","sponsor":"Bayer","startDate":"2023-08-31","conditions":"Non-metastatic Castration-resistant Prostate Cancer","enrollment":1375},{"nctId":"NCT04070209","phase":"PHASE2","title":"Management of Oligoprogressive Castration Resistant Prostate Cancer (PCS X)","status":"RECRUITING","sponsor":"Sir Mortimer B. Davis - Jewish General Hospital","startDate":"2020-10-19","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer","enrollment":66},{"nctId":"NCT03724747","phase":"PHASE1","title":"Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-12-18","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":63},{"nctId":"NCT06498921","phase":"","title":"An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-07-15","conditions":"Metastatic Hormone-sensitive Prostate Cancer","enrollment":106},{"nctId":"NCT06204302","phase":"","title":"An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-01-05","conditions":"Non-metastatic Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer","enrollment":1800},{"nctId":"NCT05362149","phase":"","title":"An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-04-04","conditions":"Non-metastatic Castration-resistant Prostate Cancer","enrollment":870},{"nctId":"NCT02933801","phase":"PHASE2","title":"ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.","status":"TERMINATED","sponsor":"Swiss Cancer Institute","startDate":"2017-03-31","conditions":"Prostate Cancer Metastatic, Prostate Cancer","enrollment":92},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04157088","phase":"PHASE2","title":"Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)","status":"TERMINATED","sponsor":"Bayer","startDate":"2019-12-17","conditions":"Prostatic Cancer, Castration-Resistant","enrollment":30},{"nctId":"NCT05249712","phase":"PHASE2","title":"Efficacy and Safety of Darolutamide Combined With ADT in High-risk/Very High-risk Localized Prostate Cancer","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2022-01-01","conditions":"Prostate Cancer","enrollment":30},{"nctId":"NCT02200614","phase":"PHASE3","title":"Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-09-12","conditions":"Prostate Cancer Non-Metastatic, Castration-Resistant","enrollment":1509},{"nctId":"NCT03704519","phase":"PHASE1","title":"Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.","status":"COMPLETED","sponsor":"Bayer","startDate":"2018-10-23","conditions":"Cerebrovascular Circulation","enrollment":26},{"nctId":"NCT03004534","phase":"EARLY_PHASE1","title":"A Study to Evaluate Changes in Human Breast Cancer Tissue Following Short-Term Use of Darolutamide","status":"COMPLETED","sponsor":"Translational Research in Oncology","startDate":"2017-09-05","conditions":"Breast Cancer Female","enrollment":36},{"nctId":"NCT02894385","phase":"PHASE1","title":"Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-09-13","conditions":"Pharmacokinetics, Hepatic Insufficiency, Renal Insufficiency","enrollment":29},{"nctId":"NCT03237416","phase":"PHASE1","title":"Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-08-02","conditions":"Prostatic Neoplasms","enrollment":15},{"nctId":"NCT03048110","phase":"PHASE1","title":"Drug-drug Interaction (DDI) Study to Assess ODM-201 as a Victim of CYP3A4 Inhibition or Induction","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-02-15","conditions":"Biological Availability","enrollment":15},{"nctId":"NCT02363855","phase":"PHASE1","title":"Phase 1 Dose Escalation Study of BAY 1841788 in Japanese Metastatic Castration-resistant Prostate Cancer (mCRPC) Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-02-23","conditions":"Prostatic Neoplasms","enrollment":9},{"nctId":"NCT02671097","phase":"PHASE1","title":"Drug-drug Interaction Study Using Rosuvastatin as a Breast Cancer Resistant Protein (Efflux Transporter), Organic Anion-transporting Polypeptide (OATP)1B1, and OATP1B3 (Uptake Transporters) Probe Substrate","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02","conditions":"Healthy Volunteers, Pharmacokinetics, Drug Interaction","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["NUBEQA","Nubeqa"],"phase":"phase_3","status":"active","brandName":"Darolutamide (BAY 1841788)","genericName":"Darolutamide (BAY 1841788)","companyName":"Canadian Cancer Trials Group","companyId":"canadian-cancer-trials-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Darolutamide is a non-steroidal androgen receptor inhibitor that blocks androgen signaling in prostate cancer cells. Used for Non-metastatic castration-resistant prostate cancer (nmCRPC), Metastatic hormone-sensitive prostate cancer (mHSPC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}